Nicosan™ is an antisickling drug used for prevention of symptoms and pain management in patients with sickle cell disease (SCD). It is prepared from a mixture of four Nigerian plant materials: the seeds of Piper guineense, the stems of Pterocarpus osun, the fruits of Eugenia caryophyllum, and the leaves of Sorghum bicolor.
Nicosan™ was developed at the Nigerian National Institute for Pharmaceutical Research and Development (NIPRD). It had been produced by Xechem International, Inc., an American-based company that filed for bankruptcy. It is unclear when production will resume.
Although the evidence supporting the use of Nicosan™ for SCD is promising, it should be noted that most of these studies were carried out by the Nigerian government, which has a vested interest in the drug's success. Further large-scale, randomized, controlled studies need to be performed before conclusions may be drawn.

Related Terms

Ashanti pepper, Benin pepper, Eugenia caryophyllum, false cubeb, Guinea cubeb, Guinea pepper, Hemoxin™, kale (Nigeria), kukauabe (Nigeria), masoro, Niprisan®, Nix-0699, Piper guineense, Pterocarpus osun, sasema (Nigeria), sorghum, Sorghum bicolor, Sorghum japonicum, soro wisa (Nigeria), uziza pepper, vanillin, West African pepper.

evidence table

These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.
Sickle cell disease (Grade: B)
According to available clinical trials, Nicosan™ appears to be safe and effective for preventing and reducing sickle cell disease (SCD) crises associated with severe pain. Future research with larger sample sizes are needed to assess the role of Nicosan™ in the management of patients with SCD.